Skip to content

Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders

Relationship Between Premorbid Personality Traits and Cognitive and Behavioral Disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06059313
Enrollment
120
Registered
2023-09-28
Start date
2023-12-14
Completion date
2026-12-14
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavioral Variant of Frontotemporal Disorder (bvFTD), Bipolar Disorder, Frontal Variant of Alzheimer Disease, Phenocopy Frontotemporal Dementia (phFTD)

Keywords

bvFTD, fvAD, phFTD, bipolar disorder,personality

Brief summary

Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social cognition. Symptoms vary both quantitatively and qualitatively from disease to another and from person to person. It cannot be completely excluded that in some cases, factors of susceptibility such as premorbid personality traits lead to frontal fragility. The study will assess the relationship between premorbid profile using NEO-PI 3 inventory and cognitive and behavioral/psychobehavioral manifestations in patients with behavioral variant of frontotemporal disorder (bvFTD), phenocopy frontotemporal dementia (phFTD), frontal variant of Alzheimer disease, bipolar disorder characterized with frontal damages.

Interventions

OTHERSubmission of the NEO-PI-3 questionnaire

The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

OTHERSubmission of the Interpersonal Reactivity Index questionnaire (IRI)

The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

: * Patients with behavioral variant of frontotemporal disorder (bvFTD) according to Rascovsky criteria (2011) or patients with phénocopy frontotemporal dementia (phFTD) who fulfill criteria for possible bvFTD and have no imaging abnormalities or patients with frontal variant of Alzheimer disease according to Ossenkopele criteria (2022), or patient with bipolar disorder according to CIM 10 criteria * Score for Mini-mental state examination ≥ 18 * Patient with caregiver who has who has known him/her in the 10 years preceding the disease onset. * Patient and caregiver consents (no opposition)

Exclusion criteria

: * Patient with no caregiver * Pregnant or breast feeding women

Design outcomes

Primary

MeasureTime frameDescription
Premorbid personality traitsBaselinePremorbid personality traits will be assessed by the NEO- NEO Personality Inventory-3 (NEO-PI-3). The NEO PI-3 measures the five major domains of personality: Neuroticism, Extraversion, Openness to experience, Conscientiousness and Agreeableness. Each domain is defined by 6 facets. NEOPI-3 includes 240 items and responses are made on a 5-point Likert -type scale ranging from strongly Disagree to strongly agree. The NEOPI 3 will be completed by a caregiver who has known the patient in the 10 years preceding the disease onset.

Secondary

MeasureTime frameDescription
Interpersonal Reactivity Index (IRI)BaselineIRI is a 28-item questionnaire measuring 4 aspects of empathy : perspective-taking, fantasy, empathic concern, personal distress. Each answer is rated from 1 (does not describe me well) to 5 (describes me very well).

Countries

France

Contacts

CONTACTClaire BOUTOLEAU-BRETONNIERE, PH
claire.boutoleaubretonniere@chu-nantes.fr33 2 40 16 54 22
CONTACTLaetitia BARBIN
laetitia.barbin@chu-nantes.fr33 2 40 16 59 42

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 30, 2026